A Phase II Study of High-Dose-Rate Afterloading Brachytherapy as Monotherapy for the Treatment of Localized Prostate Cancer

Corner, Carie; Rojas, Ana M.; Bryant, Linda; Ostler, Peter; Hoskin, Peter

doi:10.1016/j.ijrobp.2007.12.026

Cited by 72 publications

(32 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Publications on prostate cancer patients treated with conventional fractionated EBRT combined with hypofractionated IMRT boosts 96 of 2 fractions of 5-8 Gy (median follow-up of 63 months) or with concomitant boosts 97,98 in 28 fractions of 2.5 Gy and 25 fractions of 2.7 Gy (median follow-up of 46 and 39 months, respectively) concluded that these treatments were feasible and well tolerated. The results on EBRT treatments in combination with HDRBT boosts 65,66,[99][100][101][102][103][104][105] with median follow-up ranging from 40 to 105 months (2 fractions Â 5-15 Gy, 3 fractions Â 3-6.5 Gy, or 4 fractions Â 3-6 Gy) and extreme hypofractionated treatments of HDRBT delivered as monotherapy [106][107][108][109][110][111][112] at median follow-up of 22-65 months (3 fractions Â 10.5 Gy, 4 fractions Â 8.5-9.5 Gy, 6 fractions Â 6.75-7 Gy, 8 fractions Â 6 Gy, or 9 fractions Â 6 Gy) or stereotactic body radiosurgery [113][114][115] 119,120 median follow-up: 32 months for the hypofractionation regimens and 35 months for the conventional). Despite differences in dose prescription, delivery methods, patient selection according to prognostic factors, short follow-up in many studies, and the use of androgen deprivation therapy in some patients, the clinical experience with hypofractionation seems to be consistent with a low a/b ratio for prostate cancer.…”

Section: Feasibility Of the Hypofractionation Regimensmentioning

confidence: 99%

What do we know about the α/β for prostate cancer?

2012

View full text Add to dashboard Cite

Since last decade, the debate on the parameter which reflects prostate cancer sensitivity to fractionation in a radiotherapy treatment, the α/β, has become extensive. Unlike most tumors, the low labeling indices (LI) and large potential doubling time that characterize the prostate tumor led some authors to consider that it may behave as a late responding tissue. So far, the existing studies with regard to this subject point to a low value of α/β, around 2.7 Gy, which may be considered as a therapeutic gain in relation to surrounding normal tissues by using fewer and larger fractions. The aim of this paper is to review several estimates that have been made in the last few years regarding the prostate cancer α/β both from clinical and experimental data, as well as the set of factors that have potentially influenced these evaluations.

show abstract

Section: Feasibility Of the Hypofractionation Regimensmentioning

confidence: 99%

What do we know about the α/β for prostate cancer?

2012

View full text Add to dashboard Cite

show abstract

“…(17) tarafından bildirilmiştir. Bunu takiben düşük riskli prostat kanseri tanılı hastalarda tek başına HDR brakiterapi tedavisinin sonuç-larını bildiren farklı çalışmalar yayınlanmıştır (16,18,19) . Bu çalışmaların sonucunda, HDR prostat brakiterapisi kabul edilebilir bir toksisite ile hastalar tarafından iyi tolere edilen bir tedavi olarak bildirilmiştir.…”

Section: Hdr Brakiterapi Sonuçlarıunclassified

“…(20) HDR prostat brakiterapisinin LDR prostat brakiterapisine göre avantajlarını hedef dokuda daha iyi bir doz dağılımı elde edilmesi şeklinde bildirmiş-lerdir. Yaygın olarak kullanılan tedavi rejimleri 31,5-54 Gy/3-9 fr (fr başına 8,5-10,5 Gy) olup toplam tedavi süresi 2-5 gün arasında değişmektedir (17)(18)(19)(20) . Bu çalışmalara göre 5 yıllık biyokimyasal nükssüz sağ-kalım oranı %79-93 olarak, grade II ve üzeri toksisite oranı %10-14 olarak bildirilmiştir.…”

Section: Hdr Brakiterapi Sonuçlarıunclassified

See 1 more Smart Citation

High Dose Rate Brachytherapy Application in Prostate Cancer Treatment

Özen¹,

Parlar²,

Saynak³

et al. 2016

Okmeydani Medical Journal

View full text Add to dashboard Cite

show abstract

“…Different fractionation schedules are described in the literature with the single dose ranging from 6 to 10.5 Gy and the number of fractions ranging from three to nine with a minimum interval of 6 h between the subsequent fractions. Generally, for logistic and economic reasons one implant and one treatment plan are used [4,10,11,16,18,[25][26][27]. However, there are no standard criteria or guidelines for repeating imaging and dosimetry for each fraction after a single implant.…”

Section: Introductionmentioning

confidence: 99%